Banting Memorial Lecturer
David Dunger presented the Banting Memorial Lecture at the 2016 Diabetes UK Professional Conference in March
Professor of Paediatrics, University of Cambridge
David Dunger is Professor of Paediatrics at the University of Cambridge. He received his training in paediatric diabetes and endocrinology at the Hospital for Sick Children, Great Ormond Street. Subsequently he moved to Oxford where he built on the legacy of David Baum developing a high quality and research based diabetes service. In 2000 he took up a Chair in Paediatrics at University of Cambridge.He is a Faculty member of the Wellcome Trust-MRC Institute of Metabolic Science and Clinical Lead of the Cambridge Clinical Trials Unit.
His particular research interests include the physiological and psychological determinants of glycaemic control in adolescents with Type 1 diabetes. His studies identified a critical role for the growth hormone/insulin-like growth factor 1 axis in determining insulin requirements, glycaemic control and potential risk of early complications during adolescence.
David is the recipient of several research awards: Nabarro medal awarded by the IDF; the Research Award of the European Society for Paediatric Endocrinology; Andrea Prader Prize from the European Society for Paediatrics Endocrinology; and the James Spence Medal. He is also a Fellow of the Academy of Medical Science and an NIHR Senior Investigator.
Reducing life-time risk of complications in adolescents with Type 1 diabetes
Adolescence is a challenging period of life for any young person, and for young people with diabetes, physiological and psychological factors can result in a deterioration in glycaemic control. Puberty may be an additional risk factor impacting on the life-time risk for renal and cardiovascular complications. Our longitudinal studies have identified increases in urinary albumin excretion throughout childhood linked to the development of microalbuminuria and a generalised endotheliopathy towards the end of puberty. Screening of subjects recruited to the Adolescent Intervention Trial (AdDIT) exploring the effects of statins and ACE inhibitors confirm that these early changes in albumin excretion are related to both diabetic nephropathy and cardiovascular risk independent of glycaemic control. Thus, as well as current attempts to improve glycaemic control through enhanced targeted insulin delivery we have explored the role of ACE inhibitors and statins in providing cardio renal protection during adolescence.